期刊文献+

灯盏生脉胶囊辅助治疗慢性肺源性心脏病的临床观察 被引量:5

下载PDF
导出
摘要 目的探讨灯盏生脉胶囊治疗肺源性心脏病的临床疗效。方法将80例患者随机分为两组,观察组40例,对照组40例,两组患者均给予适当的抗炎、止咳化痰、氧疗、纠正右心功能衰竭等常规综合治疗。观察组在此基础上加用灯盏生脉胶囊2粒,3次/d。4周为1个疗程,连续服用2个疗程。比较两组患者的治疗效果和治疗前后的血气指标及血液流变学指标的变化。结果经过2个疗程的治疗后,观察组显效率和总有效率均明显高于对照组,两组比较差异有统计学意义(P<0.05);治疗后,观察组的PaO2值高于对照组,PaCO2值明显低于对照组,两组比较差异有统计学意义(P<0.05);观察组治疗后血液流变学相关指标明显低于治疗前,与对照组比较,差异有统计学意义(P<0.05);观察组治疗前后比较,肺动脉收缩压明显降低,差异有统计学意义(P<0.01),与对照组治疗后比较,观察组治疗后肺动脉收缩压明显降低,差异有统计学意义(P<0.05)。结论灯盏生脉胶囊是治疗肺源性心脏病的良好辅助用药,值得临床推广应用。
出处 《广东医学》 CAS CSCD 北大核心 2011年第24期3276-3277,共2页 Guangdong Medical Journal
  • 相关文献

参考文献8

二级参考文献32

  • 1易进海.麦冬研究进展[J].华西药学杂志,1993,8(1):32-38. 被引量:41
  • 2石森林,徐莲英.灯盏花制剂的临床应用[J].中国临床药学杂志,2004,13(6):379-382. 被引量:11
  • 3方云祥,李灿,王志纯,彭军.人参总皂甙对犬冠脉流量和血液动力学的影响[J].湖南医科大学学报,1995,20(1):5-8. 被引量:51
  • 4脑血管疾病分类(1995)(中、英文)[J].中华神经科杂志,1996,29(6):376-378. 被引量:430
  • 5Celermajer DS. Testing endothelial function using ultrasound [J]. Jcardiovase Pharmacol, 1988,32 (suppl) : 29 - 32
  • 6Blake GJ,Ridker PM. Novel clinical markers of vascular wall inflammation[J]. Circ Res, 2001,89 (9), 763 - 771
  • 7Ferranti SD, Rifai N. C- reactive protein and cardiovascular disease:A review of risk prediction and intervention[J]. Clin Chim Acta,2002,317(1) :1 - 15
  • 8Chias S, Ludlam CA, Fox KA, et al. Acute systemic inflammation enhances endotheliurn dependent tissue plasminogen activator release in men[J]. J Am Coil Cardiol, 2003,41 (2) : 333 - 339
  • 9阮英茆,中华结核和呼吸杂志,1991年,14卷,5页
  • 10团体著者,中华病理学杂志,1990年,19卷,22页

共引文献538

同被引文献53

  • 1余吉西,李林林.灯盏细辛注射液治疗冠心病心绞痛50例[J].广东医学,2005,26(9):1281-1281. 被引量:10
  • 2LLOYD JONES D, ADAMS R, CARNETHON M, et al. Heart disease and stroke statistics -2009 update: a report from the American Heart Association Statistics Committee and Stroke Statis- tics Subcommittee[ J]. Circulation, 2009, 119 (3) : 480 - 486.
  • 3KUOA H K, AL SNIH S, KUO Y E, et al. Chronic inflamma- tion, albuminuria, and functional disability in older adults with cardiovascular disease: the National Health and Utrition Examina-tion Survey, 1999 - 2008 [ J]. Atheroscierosis, 2012, 222 (2) : 502 - 508.
  • 4MUELLER T, GEGENHUBER A, POELZ W, et al. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure[ J ]. Heart, 2005, 91 (5) : 606 -612.
  • 5JAMES L, GARLOS A, SAIF A, et al. The N - terminal pro - BNP investigation of dyspnea in the emergency department (PRIDE) study[J]. Am J Cardiol, 2005, 95(8) : 948 -954.
  • 6PEARSON T, MENSAH G, ALEXANDER R, et al. Markers of inflammation and cardiovascular disease - application to clinical and public health practice : a statement for healhcare professionals from the Centers for Disease Control and Prevention and the American Heart Association [ J ]. Circulation, 2003, 107 ( 3 ) : 499 -511.
  • 7SAKATA Y, YAMAMOTO K, MANO T, et al. Activation of ma- trixlnetallo proteinases precedes left ventrieular remodeling in hy- pertensive heart failure rats: its inhibition as a primary effect of Angiotensin -converting enzyme inhibitor[J]. Cioulation, 2004, 109(17) : 2143 -2149.
  • 8IKONOMIDIS I, NIKOLAOU M, DIMOPOULOU L, et al. Asso- ciation of left ventficular diastolic dysfunction with elevated NT - pro- BNP in general intensive care unit patients withpreserved e- jection fraction: a complementary role of tissue Doppler imaging parameters and NT - pro - BNP levels for adverse outcome [ J ]. Shock, 2010, 33(2) : 141 - 148.
  • 9GREWAL J, MCKELVIE R, LONN E, et al. BNP and NT - proBNP predict echo eardiographic severity of diastolic dysfunction [J]. Eur J Heart Fait, 2008, 10(3) : 252 -259.
  • 10PARK H S, KIM /4, SOl-IN J I4, et al. Combination of uric acid and NT - BNP: a more useful prognostic marker for short - term clinical outcomes in patients with acute heart failure[ J]. Korean J Intern Med, 2010, 25(3) : 253 -259.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部